BCG, the only licensed live tuberculosis vaccine, is less virulent than wild-type M. bovis and Mtb12–14 and elicits immune activation via cytokines such as IFN-γ that are central to vaccine-derived immunity. The gene discussed is IFNG; the disease is tuberculosis.